Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 8/20 | 0.47 |
| ▸ | TNF | P01375 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | NAPEPLD | Q6IQ20 | 3/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23068586 | 1.00 | PDE4D (0.47) | PDE4DTNFPDE10AEGLN1NAPEPLD | |
| SCHEMBL30607013 | 1.00 | PDE4D (0.47) | PDE4DTNFPDE10AEGLN1NAPEPLD | |
| SCHEMBL12921249 | 0.91 | PDE4D (0.41) | PDE4DPDE10AEGLN1NAPEPLDCCR4 | |
| SCHEMBL23068579 | 0.87 | PDE4D (0.44) | PDE4DNAPEPLDCCR4 | |
| SCHEMBL30607024 | 0.87 | PDE4D (0.44) | PDE4DNAPEPLDCCR4 | |
| SCHEMBL23068578 | 0.87 | PDE4D (0.44) | PDE4DNAPEPLDCCR4 | |
| SCHEMBL26968909 | 0.86 | PDE4D (0.42) | PDE4D | |
| SCHEMBL30607017 | 0.86 | PDE4D (0.43) | PDE4DTNFPDE10AEGLN1 | |
| SCHEMBL23068567 | 0.86 | PDE4D (0.43) | PDE4DTNFPDE10AEGLN1 | |
| SCHEMBL23068564 | 0.86 | PDE4D (0.43) | PDE4DTNFPDE10AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3724194-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | claimed |
| CN-111712502-B | Substituted azetidine dihydro-thienopyrimidines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2023-10-27 | — | — | CN | claimed |
| US-11292799-B2 | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-05 | — | — | US | claimed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | claimed |
| CN-111712502-A | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-09-25 | — | — | CN | claimed |
| EP-3724194-B1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2023-12-27 | — | — | EP | disclosed |
| CN-111712502-B | Substituted azetidine dihydro-thienopyrimidines and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11292799-B2 | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | UNION therapeutics A/S (DK) | 2022-04-05 | — | — | US | disclosed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2021-03-11 | — | — | US | disclosed |
| CN-111712502-A | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-09-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292799-B2 | Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | PDE2A, PDE5A, PDE3A | PDE4D 12/4885TNF 3555/4885PDE10A 30/4885 |
| US-20210070769-A1 | SUBSTITUTED AZETIDINE DIHYDROTHIENOPYRIMIDINES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE2A, PDE5A, PDE3A | PDE4D 12/4885TNF 3555/4885PDE10A 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.